Form 8-K - Current report:
SEC Accession No. 0001564590-21-023676
Filing Date
2021-05-05
Accepted
2021-05-05 08:57:53
Documents
12
Period of Report
2021-05-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K dvax-8k_20210503.htm   iXBRL 8-K 38142
  Complete submission text file 0001564590-21-023676.txt   169263

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA dvax-20210503.xsd EX-101.SCH 5772
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE dvax-20210503_lab.xml EX-101.LAB 19478
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dvax-20210503_pre.xml EX-101.PRE 11627
5 EXTRACTED XBRL INSTANCE DOCUMENT dvax-8k_20210503_htm.xml XML 3558
Mailing Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 21891372
SIC: 2834 Pharmaceutical Preparations